Capital One Financial Comments on GlycoMimetics, Inc.’s Q1 2024 Earnings (NASDAQ:GLYC)

GlycoMimetics, Inc. (NASDAQ:GLYC) – Research analysts at Capital One Financial issued their Q1 2024 EPS estimates for GlycoMimetics in a research note issued to investors on Monday, May 6th. Capital One Financial analyst N. Quibria expects that the biotechnology company will post earnings of ($0.17) per share for the quarter. Capital One Financial currently has a “Equal Weight” rating on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.54) per share. Capital One Financial also issued estimates for GlycoMimetics’ Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.62) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.93) EPS.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The firm had revenue of $0.01 million for the quarter.

Several other brokerages also recently commented on GLYC. StockNews.com downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. HC Wainwright reaffirmed a “neutral” rating on shares of GlycoMimetics in a research report on Monday.

GlycoMimetics Stock Performance

NASDAQ GLYC opened at $0.30 on Thursday. The stock has a 50-day simple moving average of $2.37 and a 200 day simple moving average of $2.32. GlycoMimetics has a twelve month low of $0.27 and a twelve month high of $3.53. The stock has a market capitalization of $19.23 million, a PE ratio of -0.51 and a beta of 2.30.

Hedge Funds Weigh In On GlycoMimetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisor OS LLC bought a new stake in shares of GlycoMimetics in the 4th quarter worth approximately $238,000. MJP Associates Inc. ADV bought a new stake in shares of GlycoMimetics in the 4th quarter worth about $238,000. Finally, Acuta Capital Partners LLC bought a new stake in GlycoMimetics during the third quarter worth about $41,000. 75.19% of the stock is currently owned by institutional investors.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.